(Q38264051)

1 September 2017

1 reference

title

Luseogliflozin for the treatment of type 2 diabetes (English)

1 reference

1 September 2017

1 reference

Yutaka Seino

1

1 reference

PubMed ID

25359155

1 September 2017

language of work or name

English

0 references

publication date

30 October 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

18

1 reference

1 September 2017

2741-2749

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

DPP-4 inhibition and islet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Tofogliflozin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.978290

10.1517/14656566.2014.978290

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25359155